Pharmaceutical Technology

AUGUST 12, 2022

By 2028, the market is expected to reach $25 billion, with a compound annual growth rate (CAGR) of 46.6%. The standard first-line treatment for DLBCL is a chemotherapy regimen, alongside the monoclonal antibody rituximab. There are a total of 124 companies involved in CAR-T cell drug development for this indication.

Immunity 52

Immunity Immunization Chemotherapy Compounding 52

Pharmaceutical Technology

FEBRUARY 13, 2023

Both degraders, ARV-110 (bavdegalutamide) and ARV-766, are being developed by Arvinas. GlobalData’s analyst consensus forecast database estimates peak annual sales for ARV-110 of $325 million in 2028. Faslodex will be administered in the control arm of the Phase III study, allowing for direct comparison between the two ER degraders.

Dosage 59

Dosage Chemotherapy Compounding Immunity 59

Express Pharma

APRIL 3, 2023

per cent, and 3 per cent, respectively, between 2022 and 2028. In recent years, key China-based companies like RemeGen, Jiangsu-Hengrui Medicine , and Zhejiang Medicine/NovoCodex have ventured into the ADC-based treatment space through active research and development. per cent, 1.6

Chemotherapy 95

Chemotherapy Compounding Drug Development 95